December 30, 2014
Will Biotech Fire on All Cylinders in 2015?
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early 2014 before rebounding, essentially following the upward trend that most experts forecast. What is in store for 2015? The Life Sciences Report turned to MTSL’s Editor, John McCamant and WBB Securities’ Steve Brozak for insight.
Consider the statistics. In 2013, most major biotech indices, such as the NASDAQ Biotechnology Index (NBI) and the NYSE ARCA Biotech Index (BTK), posted healthy double-digit gains. It appears 2014 will end on the same upward trajectory: Year-to-date, the NBI is up about 34%, and the BTK is up about 48%. As 2015 approaches, the question on every investor’s mind is: Can the market continue its bonanza-style growth? And which companies or sectors will be the most attractive and lucrative?
Steve Brozak of WBB Securities and John McCamant, editor of the Medical Technology Stock Letter, have some ideas.